MENLO PARK, Calif.--(BUSINESS WIRE)--Aug 9, 2018--Frazier Healthcare Partners announced the addition of two new members to its Life Sciences team: Tracy Saxton, Ph.D. as an Entrepreneur-in-Residence (EIR), and Vanessa Bhark as a Senior Associate.

As an EIR, Dr. Saxton will focus on company creation efforts. She is the founder and CEO of Aucupo Biosciences, a newly formed Frazier search company focused on identifying novel therapeutics for patients with unmet medical need. Prior to joining Frazier, Dr. Saxton held investment positions with Pivotal bioVenture Partners, the Roche Venture Fund (RVF) and SV Life Sciences Advisers (SVLSA), where she focused on the biopharmaceutical sector. Dr. Saxton previously held positions at Tularik (acquired by Amgen) and Threshold Pharmaceuticals. She began her career as a drug discovery scientist and moved to leadership roles in Regulatory Affairs, Clinical Development and Project Management.

As a Senior Associate, Ms. Bhark will focus on evaluating investments and creating new ventures in life sciences. Prior to joining Frazier, she was in Corporate Development at Gilead Sciences, where she structured and led the negotiation of licenses, collaborations, and acquisitions across therapeutic areas. Previously, Ms. Bhark was a Business Development Manager at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where she led the evaluation and recommendation of licensing and acquisition opportunities for Janssen's $3.2 billion Infectious Disease Franchise. In addition, she worked for Morgan Stanley in the Equity Research Division with a focus on public biotech investments.

“We are excited to have Tracy and Vanessa join our team; collectively, they bring significant skill sets in venture, drug development, and business development to the life sciences venture group,” said Jamie Topper, M.D., Ph.D., Managing General Partner with the Frazier Life Sciences team.

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.2 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.

For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

About Aucupo Biosciences, Inc.

Headquartered in Menlo Park, CA, Aucupo Biosciences is a newly formed Frazier search company focused on identifying novel therapeutics for patients with unmet medical need.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180809005178/en/

CONTACT: Frazier Healthcare Partners

Liz Park, 650-319-1831

liz.park@frazierhealthcare.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY OTHER HEALTH PROFESSIONAL SERVICES CONSULTING FINANCE

SOURCE: Frazier Healthcare Partners

Copyright Business Wire 2018.

PUB: 08/09/2018 08:00 AM/DISC: 08/09/2018 08:01 AM

http://www.businesswire.com/news/home/20180809005178/en